FDA Approves Garzulys (insulin aspart-fsan), a Biosimilar to NovoLog
BLA FilingapprovedGarzulysNovoLogPositive
AI Analysis
Summary
The FDA approved Garzulys (insulin aspart-fsan), a biosimilar to NovoLog developed by Meitheal Pharmaceuticals, marking a regulatory success for the Chicago-based biopharmaceutical company focused on generic injectable medicines.
Outcome Details
FDA approved Garzulys (insulin aspart-fsan), a biosimilar to NovoLog
Importance:8/10
Sentiment:
0.90
FDA approvalbiosimilarinsulininjectable
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 30, 2026 2:07 AM